| 06/10/2026 3:15 PM | Eikon Therapeutics (1861123) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/01/2026 6:30 AM | Eikon Therapeutics (1861123) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/13/2026 4:24 PM | Eikon Therapeutics (1861123) Subject PERLMUTTER ROGER M (1184228) Filed by | Form SCHEDULE 13G | |
| 05/11/2026 3:13 PM | Eikon Therapeutics (1861123) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 3:05 PM | Eikon Therapeutics (1861123) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 10:13 AM | Eikon Therapeutics (1861123) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 03/30/2026 7:02 AM | Eikon Therapeutics (1861123) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/30/2026 6:09 AM | Eikon Therapeutics (1861123) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/04/2026 3:58 PM | Bowie Alfred Lloyd Jr. (2104152) Reporting Eikon Therapeutics (1861123) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 3:59 PM | Baynes Roy D. (1680739) Reporting Eikon Therapeutics (1861123) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/04/2026 3:59 PM | Eikon Therapeutics (1861123) Issuer Thorner Benjamin Bruno (2102118) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for EIKN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Eikon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 02/12/2026 5:48 PM | Column Group IV GP, LP (1796356) Filed by Eikon Therapeutics (1861123) Subject | Form SCHEDULE 13D | |
| 02/09/2026 8:19 PM | Column Group IV GP, LP (1796356) Reporting Column Group IV, LP (1796354) Reporting Column Group IV-A, LP (1796353) Reporting Column Group Opportunity III GP, LP (1932874) Reporting Column Group Opportunity III, LP (1931825) Reporting Eikon Therapeutics (1861123) Issuer Kutzkey Tim (1614186) Reporting Svennilson Peter (1606074) Reporting TCG Opportunity III GP, LLC (1932445) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 6:37 PM | Eikon Therapeutics (1861123) Issuer Foresite Capital Fund IV, L.P. (1704131) Reporting Foresite Capital Fund V, L.P. (1792204) Reporting Foresite Capital Management IV, LLC (1704132) Reporting Foresite Capital Management V, LLC (1792206) Reporting Foresite Capital Opportunity Fund V, L.P. (1792205) Reporting Foresite Capital Opportunity Management V, LLC (1792207) Reporting Foresite Capital VI-A Management, LLC (1899218) Reporting Foresite Capital VI-A, LLC (1899120) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 5:25 PM | Eikon Therapeutics (1861123) Issuer Hebert Peter (1683771) Reporting Lux Co-Invest Opportunities II, L.P. (1783916) Reporting Lux Total Opportunities, L.P. (1864658) Reporting Lux Venture Partners V, LLC (1698118) Reporting Lux Ventures V, L.P. (1698008) Reporting Wolfe Josh (1830001) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 5:27 PM | Eikon Therapeutics (1861123) Issuer Wolfe Josh (1830001) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 5:33 PM | Eikon Therapeutics (1861123) Issuer FRAZIER KENNETH C (1181175) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/06/2026 3:23 PM | Eikon Therapeutics (1861123) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/06/2026 3:14 PM | Eikon Therapeutics (1861123) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/04/2026 8:59 PM | Column Group IV GP, LP (1796356) Reporting Column Group IV-A, LP (1796353) Reporting Column Group Opportunity III GP, LP (1932874) Reporting Column Group Opportunity III, LP (1931825) Reporting Eikon Therapeutics (1861123) Issuer TCG Opportunity III GP, LLC (1932445) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:30 PM | Eikon Therapeutics (1861123) Issuer Wolfe Josh (1830001) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:32 PM | Eikon Therapeutics (1861123) Issuer Huffines Robert Luther (1728221) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:34 PM | Bowie Alfred Lloyd Jr. (2104152) Reporting Eikon Therapeutics (1861123) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:35 PM | Eikon Therapeutics (1861123) Issuer Foresite Capital Fund IV, L.P. (1704131) Reporting Foresite Capital Fund V, L.P. (1792204) Reporting Foresite Capital Management IV, LLC (1704132) Reporting Foresite Capital Management V, LLC (1792206) Reporting Foresite Capital Opportunity Fund V, L.P. (1792205) Reporting Foresite Capital Opportunity Management V, LLC (1792207) Reporting Foresite Capital VI-A Management, LLC (1899218) Reporting Foresite Capital VI-A, LLC (1899120) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:19 PM | Eikon Therapeutics (1861123) Issuer Klobuchar Michael A (1871957) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:21 PM | Eikon Therapeutics (1861123) Issuer PERLMUTTER ROGER M (1184228) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:21 PM | Eikon Therapeutics (1861123) Issuer FRAZIER KENNETH C (1181175) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:22 PM | Baynes Roy D. (1680739) Reporting Eikon Therapeutics (1861123) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:23 PM | Chen Leon (1752432) Reporting Eikon Therapeutics (1861123) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:24 PM | Eikon Therapeutics (1861123) Issuer Meline David W (1444612) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:11 PM | Eikon Therapeutics (1861123) Issuer Hebert Peter (1683771) Reporting Lux Co-Invest Opportunities II, L.P. (1783916) Reporting Lux Total Opportunities, L.P. (1864658) Reporting Lux Venture Partners V, LLC (1698118) Reporting Lux Ventures V, L.P. (1698008) Reporting Wolfe Josh (1830001) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 8:18 PM | Eikon Therapeutics (1861123) Issuer Thorner Benjamin Bruno (2102118) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 02/04/2026 6:10 PM | Eikon Therapeutics (1861123) Filer | Form S-1MEF | |
| 02/04/2026 2:00 PM | Eikon Therapeutics (1861123) Filer | Form CERT | |
| 02/01/2026 11:15 PM | Eikon Therapeutics (1861123) Filer | Form EFFECT | |
| 01/28/2026 11:03 AM | Eikon Therapeutics (1861123) Filer | Form 8-A12B | |
| 01/28/2026 5:03 AM | Eikon Therapeutics (1861123) Filer | Form S-1/A | |